- Home
- PD vs VRDN Comparison
PD vs VRDN Comparison
Compare PD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | VRDN |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.7B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PD | VRDN |
|---|---|---|
| Price | $13.04 | $32.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $17.70 | ★ $40.45 |
| AVG Volume (30 Days) | ★ 3.1M | 1.5M |
| Earning Date | 11-25-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $489,207,000.00 | $70,789,000.00 |
| Revenue This Year | $8.21 | $26,257.62 |
| Revenue Next Year | $4.33 | $10.69 |
| P/E Ratio | $7.87 | ★ N/A |
| Revenue Growth | 7.01 | ★ 23340.07 |
| 52 Week Low | $11.13 | $9.90 |
| 52 Week High | $20.00 | $34.04 |
Technical Indicators
Market Signals| Indicator | PD | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 59.07 |
| Support Level | $12.69 | $32.00 |
| Resistance Level | $13.11 | $33.03 |
| Average True Range (ATR) | 0.36 | 1.09 |
| MACD | 0.14 | -0.30 |
| Stochastic Oscillator | 80.60 | 39.93 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).